Check out this morning's top movers from around Wall Street, compiled by The Fly. 

HIGHER -

• Coty (COTY) up 13% after announcing it will will acquire a 20% ownership interest in Kim Kardashian West's beauty business for $200M
• Boeing (BA) up 6% after the New York Times reported the company has received Federal Aviation Administration approval to start test flights of its 737 Max to demonstrate that it can fly safely with new flight control software
• Nikola (NKLA) up 6% after announcing preorders are available for its electric pickup, Nikola Badger
• Landcadia (LCA) up 36% after announcing that Landcadia II has entered into a purchase agreement to acquire Golden Nugget Online Gaming, a U.S. online real money casino owned by Tilman Fertitta
• Altimmune (ALT) up 13% after announcing it was awarded $4.7M from the U.S. Army Medical Research & Development Command to fund its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19

LOWER -  

• Facebook (FB) and Twitter (TWTR) down 3% and 2%, respectively, after a number of companies, including Starbucks (SBUX), have joined an advertisement boycott of the social media companies
• Durect (DRRX) down 3% after announcing that Gilead Sciences (GILD) has provided notice that, effective as of December 22, it is terminating the license agreement and a related R&D agreement between Gilead and the company related to the development and commercialization of a long-acting injectable HIV investigational product utilizing Durect's SABER technology
• Beyond Meat (BYND) down 4% after Barclays analyst Benjamin Theurer double downgraded shares to Underweight from Overweight with a price target of $115, up from $100
• Intercept (ICPT) and CymaBay (CBAY) down 38% and 3%, respectively, after Intercept announced that the FDA has issued a complete response letter saying the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH